ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for monitor Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.

BCEL Atreca Inc

0.15
0.00 (0.00%)
06 May 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type
Atreca Inc NASDAQ:BCEL NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 0.15 0.16 0.17 0 01:00:00

Atreca to Present at Two Upcoming Investor Conferences

14/11/2019 1:00pm

GlobeNewswire Inc.


Atreca (NASDAQ:BCEL)
Historical Stock Chart


From May 2019 to May 2024

Click Here for more Atreca Charts.

Atreca, Inc. (Atreca) (NASDAQ: BCEL), a biotechnology company focused on developing novel therapeutics based on a deep understanding of the human immune response, today announced that it will present at two upcoming investor conferences:

  • Stifel Healthcare Conference 2019Date: Tuesday, November 19, 2019Presentation Time: 10:55 a.m. ESTLocation: New York, NY
  • Evercore ISI HealthCONx ConferenceDate: Tuesday, December 3, 2019Presentation Time: 10:15 a.m. ESTLocation: Boston, MA

Live audio webcasts of the presentations can be accessed through the Events & Presentations section of the company's website at ir.atreca.com. Archived replays of the webcasts will be available on the company's website for 90 days following each live presentation.

About Atreca, Inc. Atreca is a biopharmaceutical company utilizing its differentiated platform to discover and develop novel antibody-based immunotherapeutics to treat a range of solid tumor types. Atreca’s discovery platform relies on the human immune system to discover unique antibody-target pairs from patients experiencing an active immune response against their tumors. These unique antibody-target pairs represent a potentially novel and previously unexplored landscape of immuno-oncology targets and provide the basis for novel clinical therapeutic candidates such as ATRC-101, the company’s lead clinical candidate. The company expects to file an Investigational New Drug application for ATRC-101 by the end of 2019 and to commence a Phase 1b study in multiple solid tumor types in early 2020. For more information on Atreca, please visit www.atreca.com.

ContactsAtreca, Inc. Herb Cross Chief Financial Officer info@atreca.com

Investors: Alex Gray, 650-779-9251, ext. 251 agray@atreca.com

Source: Atreca, Inc.

1 Year Atreca Chart

1 Year Atreca Chart

1 Month Atreca Chart

1 Month Atreca Chart

Your Recent History

Delayed Upgrade Clock